Newsfeeds - Spark Newswire

1 minute read

Raymond James Initiates Coverage On ProQR Therapeutics with Strong Buy Rating, Announces Price Target of $19

February 1, 8:16 AM

Raymond James analyst Steven Seedhouse initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Strong Buy rating and announces Price Target of $19.

PRQR

2 minute read

16 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

February 1, 7:12 AM

Gainers

CIAN

2 minute read

News

The Usher Syndrome Coalition Announces Partnership With ProQr To Support Clinical Trial Enrollment For A Potential Therapy For USH2A Mediated Retinitis Pigmentosa

By Benzinga Newsdesk

January 31, 8:38 AM

For more than ten years, the Usher Syndrome Coalition has been working to build its international "USH Trust" registry in anticipation of the day when researchers would launch a final-stage clinical trial

PRQR

1 minute read

ProQR National Institutes Of Health ClinicalTrials.gov Listing For Co.’s ‘Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Advanced Vision Loss’

By Benzinga Newsdesk

December 15, 10:30 AM

https://clinicaltrials.gov/ct2/show/NCT05158296

PRQR

4 minute read

The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche’s Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings

By Shanthi Rexaline

November 18, 8:52 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AZN

4 minute read

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

By Shanthi Rexaline

November 14, 10:57 AM

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

1 minute read

FDA
News

ProQR Therapeutics Sponsored Study Titled ‘An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (HELIA)’ Posted To ClinicalTrials.Gov; Study Enrolling By Invitation

By Benzinga Newsdesk

October 20, 8:02 AM

https://clinicaltrials.gov/ct2/show/NCT05085964

PRQR

1 minute read

FDA
News

ProQR Therapeutics Sponsored Study Titled ‘Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 (Fuchs Focus)’ Posted To ClinicalTrials.Gov; Study Is Recruiting

By Benzinga Newsdesk

September 22, 9:12 AM

https://clinicaltrials.gov/ct2/show/NCT05052554

PRQR

1 minute read

Legal
News

ProQR Therapeutics US Patent & Trademark Office Doc Showing Patent Granted For Co.’s ‘Oligonucleotides to treat eye disease’

By Benzinga Newsdesk

September 21, 9:42 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6562&f=G&l=50&d=PTXT&p=132&S1=20210921&OS=20210921&RS=20210921

PRQR

1 minute read

News
SEC

Eli Lilly Reports In 13G Filing A 5.6% Stake In ProQR Therapeutics

By Michael Horton

September 10, 1:10 PM

-SEC Filing

LLY